AstraZeneca: Diabetes Mellitus, Type 2 trials

The registry lists 345 Diabetes Mellitus, Type 2 studies with AstraZeneca as lead sponsor. 13 are open to participants now and 149 have results posted.

Phase 1 89Phase 2 47Phase 3 122Phase 4 28No phase 65(a study in two phases counts in both)

Studies

Page 1 of 4. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 DiabetesNot yet recruitingNCT07922330Phase 3
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or OverweightRecruitingNCT07784270Phase 3
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes MellitusRecruitingNCT07776509Phase 3
A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes MellitusRecruitingNCT07775404Phase 3
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy ParticipantsRecruitingNCT07723833Phase 1
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background InsulinRecruitingNCT07664553Phase 3
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes MellitusRecruitingNCT07662213Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background DapagliflozinRecruitingNCT07662135Phase 3
A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes MellitusRecruitingNCT07662109Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes MellitusRecruitingNCT07662044Phase 3
A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical StudiesRecruitingNCT07606066
A Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in Healthy Participants, Participants With CKD and Type 2 Diabetes, Assess Home Measurements of Creatinine in a Non-Interventional Cohort, and Assess the Effect of AZD4248 on the PK of Midazolam and Metformin in Healthy ParticipantsRecruitingNCT07024823Phase 1
iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic DiseasesRecruitingNCT03549754
Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney DiseaseCompletedNCT04595370Phase 2Results posted
Study to Assess the Effect on Glucose Homeostasis of Two Dose Levels of AZD9567, Compared to Prednisolone, in Adults With Type 2 DiabetesCompletedNCT04556760Phase 2Results posted
A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes MellitusCompletedNCT04515849Phase 2Results posted
To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus PatientsCompletedNCT04445714Phase 4Results posted
A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes MellitusCompletedNCT03745937Phase 2Results posted
Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 DiabetesCompletedNCT03645421Phase 2Results posted
A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes MellitusCompletedNCT03596177Phase 2Results posted
A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.CompletedNCT03555994Phase 2Results posted
A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well ToleratedCompletedNCT03550378Phase 2Results posted
Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 DiabetesCompletedNCT03444584Phase 2Results posted
A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes PatientsCompletedNCT03387683Phase 4Results posted
Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles.CompletedNCT03338855Phase 4Results posted
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.CompletedNCT03244800Phase 2Results posted
A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 DiabetesCompletedNCT03235050Phase 2Results posted
Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years OldCompletedNCT03199053Phase 3Results posted
The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.TerminatedNCT03152084Phase 4Results posted
Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With AlbuminuriaCompletedNCT03118739Phase 2Results posted
Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart FailureCompletedNCT02917031Phase 4Results posted
ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes MellitusCompletedNCT02910089Phase 4Results posted
Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 YearsCompletedNCT02725593Phase 3Results posted
An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed ConditionsCompletedNCT02722239Phase 1Results posted
A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 DiabetesCompletedNCT02681094Phase 3Results posted
A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy SubjectsCompletedNCT02637037Phase 1Results posted
Foxiga Korea Local Phase 4 StudyCompletedNCT02564926Phase 4Results posted
A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on MetforminCompletedNCT02551874Phase 3Results posted
A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes MellitusCompletedNCT02548585Phase 1/2Results posted
A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKDCompletedNCT02547935Phase 2/3Results posted
A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.CompletedNCT02533453Phase 4Results posted
Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With SulphonylureaCompletedNCT02471404Phase 4Results posted
Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or InsulinCompletedNCT02429258Phase 4Results posted
Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes MellitusCompletedNCT02426541Phase 4Results posted
A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 DiabetesCompletedNCT02413398Phase 3Results posted
A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEICompletedNCT02370537Phase 2Results posted
A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)CompletedNCT02367066Phase 1Results posted
Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.CompletedNCT02288273Phase 4Results posted
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy AloneCompletedNCT02284893Phase 3Results posted
Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic ControlCompletedNCT02273050Phase 3Results posted
24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin MonotherapyCompletedNCT02243176Phase 4Results posted
Bioequivalence Study Coadministered to Healthy Subjects in the Fasted StateCompletedNCT02223065Phase 1Results posted
Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.CompletedNCT02157298Phase 4Results posted
Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic ControlCompletedNCT02104804Phase 3Results posted
A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes MellitusCompletedNCT01991795Phase 3Results posted
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular EventsCompletedNCT01730534Phase 3Results posted
Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 DiabetesCompletedNCT01664624Phase 1Results posted
Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy ParticipantsCompletedNCT01662999Phase 1Results posted
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes MellitusCompletedNCT01652729Phase 3Results posted
Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 DiabetesCompletedNCT01652716Phase 3Results posted
Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 DiabetesCompletedNCT01646320Phase 3Results posted
Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 DiabetesCompletedNCT01619059Phase 3Results posted
The Efficacy and Safety Study in Patients With Type 2 Diabetes MellitusCompletedNCT01608724Phase 4Results posted
Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 DiabetesCompletedNCT01606007Phase 3Results posted
Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 DiabetesCompletedNCT01554618Phase 3Results posted
PK Study of Dapagliflozin in Pediatric Subjects With T2DMCompletedNCT01525238Phase 1Results posted
Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DMTerminatedNCT01525225Phase 1Results posted
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin AloneCompletedNCT01434186Phase 3Results posted
Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and SulfonylureaCompletedNCT01392677Phase 3Results posted
Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-BrazilCompletedNCT01365091Phase 1Results posted
Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes MellitusCompletedNCT01294436Phase 3Results posted
Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes MellitusCompletedNCT01294423Phase 3Results posted
Evaluation of Dapagliflozin Taken Twice-dailyCompletedNCT01217892Phase 3Results posted
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 DiabetesCompletedNCT01204775Phase 3Results posted
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive MedicationCompletedNCT01195662Phase 3Results posted
Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus PatientsCompletedNCT01152385Phase 2Results posted
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes MellitusCompletedNCT01144338Phase 3Results posted
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor BlockerCompletedNCT01137474Phase 3Results posted
Saxagliptin Triple Oral TherapyCompletedNCT01128153Phase 3Results posted
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes MedicationsCompletedNCT01107886Phase 4Results posted
A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly SuspensionCompletedNCT01104701Phase 2Results posted
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin AloneCompletedNCT01095666Phase 3Results posted
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and ExerciseCompletedNCT01095653Phase 3Results posted
A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic AgentsCompletedNCT01077323Results posted
Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-AdministeredCompletedNCT01068743Phase 1Results posted
Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets in Healthy SubjectsCompletedNCT01068730Phase 1Results posted
Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy ParticipantsCompletedNCT01068717Phase 1Results posted
Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 DiabetesCompletedNCT01060059Results posted
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular DiseaseCompletedNCT01042977Phase 3Results posted
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and HypertensionCompletedNCT01031680Phase 3Results posted
Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 DiabetesCompletedNCT01029886Phase 3Results posted
Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) PatientsCompletedNCT01020123Phase 2Results posted
Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on MetforminCompletedNCT01006603Phase 4Results posted
Efficacy and Tolerability of Saxagliptin add-on Compared to Uptitration of Metformin in Patients With Type 2 DiabetesCompletedNCT01006590Phase 4Results posted
Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 DiabetesCompletedNCT01003184Phase 3Results posted
Dapagliflozin DPPIV Inhibitor add-on StudyCompletedNCT00984867Phase 3Results posted
Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 DiabetesCompletedNCT00976495Phase 2Results posted
Trial to Evaluate the Efficacy and Safety of Dapagliflozin in Japanese Type 2 Diabetes Mellitus PatientsCompletedNCT00972244Phase 2Results posted
A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 DiabetesCompletedNCT00960661Phase 3Results posted
An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 DiabetesCompletedNCT00960076Phase 3Results posted

All Diabetes Mellitus, Type 2 studies →AstraZeneca: all focus areas →